<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30781">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02705989</url>
  </required_header>
  <id_info>
    <org_study_id>IM014-001</org_study_id>
    <nct_id>NCT02705989</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD), and Non-Randomized, Bioavailability(BA) Study of BMS-986195 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics,
      and pharmacodynamics following single and multiple ascending oral doses of BMS-986195 in
      healthy subjects, and to assess the relative bioavailability of two formulations of
      BMS-986195 with or without food.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single oral dose of BMS-986195 as determined by medical review of adverse event reports, vital sign measurements, electrocardiograms (ECGs), and results of physical examination and laboratory tests</measure>
    <time_frame>Up to 8 days during and after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of multiple oral doses of BMS-986195 as determined by medical review of adverse event reports, vital sign measurements, electrocardiograms (ECGs), and results of physical examination and laboratory tests</measure>
    <time_frame>Up to 21 days during and after last dose</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single ascending dose of BMS-986195 or Placebo matching BMS-986195</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese-Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195 in subjects with Japanese heritage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relative Bioavailability with Food Effects (Open Label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986195</intervention_name>
    <description>Specified dose on specified day</description>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_label>Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_label>Japanese-Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_label>Relative Bioavailability with Food Effects (Open Label)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Specified dose on specified day</description>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_label>Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_label>Japanese-Multiple Ascending Dose(MAD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Body Mass Index(BMI) of 18 to 32 kilograms/meter^2

          -  Healthy male and female, first generation Japanese with confirmed paternal and
             maternal Japanese ancestry, 18-55 years old, whose residency outside of Japan does
             not exceed 10 years with a BMI of 18-30 kilograms/meter^2 inclusive.

          -  Women must not be pregnant or breastfeeding

          -  Women of Childbearing Potential (WOCBP) must agree to follow instructions for
             method(s) of contraception for the duration of treatment with study drug plus 14 days
             or longer if required.

          -  Males who are sexually active with WOCBP must agree to follow instructions for
             method(s) of contraception for the duration of treatment with study drug plus 14 days
             or longer if required.

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Known or suspected autoimmune disorder, including but not limited to rheumatoid
             arthritis, fibromyalgia, systemic lupus erythematosis, polymyalgia rheumatica, giant
             cell arteritis, Behcet's disease, dermatomyositis, multiple sclerosis, moderate to
             severe asthma, any autoimmune vasculitis, autoimmune hepatitis, or any other active
             autoimmune disease for which a subject requires medical follow-up or medical
             treatment

          -  Any history of known or suspected congenital or acquired immunodeficiency state or
             condition that would compromise the subject's immune status (example: history of
             splenectomy)

          -  Presence of any factors that would predispose the subject to develop infection e.g.,
             rectal fissures, poor dentition, open skin lesions, and presence of preexisting skin
             conditions that increase risks for injection site complications e.g. Behcet's
             Disease, Psoriasis, pustular dermatoses

          -  Any history or risk for tuberculosis (TB)

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>March 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
